Kuros raises CHF 17M

Kuros Biosciences has concluded an overallotment option granted to Zürcher Kantonalbank. In total, the company raised CHF 16.9 million from the sale of 1,351,606 shares in the rights and share offering. These sale was based on the issue price of CHF 12.50 per share. The funds will be used in preparation for the commercialization of Kuros’ products in the US and in Europe.

The new shares for the exercise of the over-allotment option will be issued out of existing authorized share capital. After completion of the capital increase, total share capital of Kuros amounts to CHF 7,800,929 consisting of 7,800,929 registered shares, an 18 % increase of the issued share capital. The first trading day of the new shares is expected to be on or around August 7, 2017. Zürcher Kantonalbank, goetzpartners and Octavian were acting as Joint Placement Agents for Kuros in the offering.

New shares in preparation for product launch
Prior to the over-allotment, Kuros sold 1,151,606 shares to existing and new investors at a price of CHF 12.50 per share. In total, Kuros raised gross proceeds of CHF 14.4 million. The new funds will fund Kuros’ commercial activities, in particular the market launch of novel products MagnetOS and Neuroseal as well as certain important activities for the ongoing Fibrin-PTH development programs.

“The new funds provide us with the financial resources needed to prepare for the commercialization of our approved products in the US and in Europe. The market launches for MagnetOs Granules and Neuroseal are expected for 2018. In addition, we are extending MagnetOs into new formulations and have recently submitted MagnetOs Putty for clearance in the US and expect a similar submission in the EU in the next months,” said Ivan Cohen-Tanugi, Chief Executive Officer of Kuros.

“We are very pleased with the rights take-up of existing shareholders and the broadening of our shareholderbase through the demand generated from new investors. The successful fund raising indicates sustained confidence and interest in our strategy, in the commercial and medical potential of our products as well as our team’s capabilities,” commented Harry Welten, Chief Financial Officer of Kuros.

The capital increase was conducted as an “at market” rights offering and an offering for shares, for which rights were not exercised. The new shares from the Company’s authorized capital were sold by way of a public offering in Switzerland and a private placement to qualified institutional investors outside of Switzerland in compliance with applicable securities laws.

(Press release/ran)